The science behind SR-3C
Clinical study #1
Vanizem® (Aframomum melegueta)
Protocol
A single-center, randomized, double-blind, crossover, placebo-controlled trial conducted over 3 days (assessment at 48 hours after a single dose) in 30 adults with a moderate level of anxiety. The tested supplement was a grains of paradise extract standardized to 10% vanilloids (Aframomum melegueta, Vanizem®), at a dose of 100 mg (the dose used in SR-3C).
Result
After 3 doses of 100 mg Vanizem®, participants reported, compared to placebo at 48 hours, a significant improvement in perceived sleep onset ease and sleep quality, a reduction in anxiety, and an increase in morning alertness.
- +31%sleep onset ease(LSEQ-GTS, 100 mg dose, p<0.05)
- +37%sleep quality(LSEQ-QOS, 100 mg dose, p<0.05)
View study
Clinical study #2
PeptiSleep™ (Nuritas)
Protocol
A single-center, randomized, single-blind, placebo-controlled consumer trial conducted over 56 days (8 weeks) in 26 adults (18-65 years, per-protocol analysis) with mild to moderate sleep disturbance. The tested supplement was PeptiSleep™, a brown rice (Oryza sativa) peptide hydrolysate, at a dose of 250 mg/day (the dose used in SR-3C).
Result
Compared to placebo, PeptiSleep™ improved several objective sleep parameters measured by an Oura connected wristband over 8 weeks: total sleep duration, deep sleep and heart rate variability (HRV), with significant differences observed at various points during follow-up (weeks 4 to 7). The 4 domains of the Leeds Sleep Evaluation Questionnaire (LSEQ) also improved, with a significant difference versus placebo in sleep onset ease (p=0.05) and sleep quality (p=0.036).
In 8 weeks
- +38 mintotal sleep per night
- +17%deep sleep
- +32%heart rate variability
Clinical study #3
Safr'Inside™ (saffron extract)
Protocol
A decentralized (nationwide, online), randomized, double-blind, placebo-controlled, three-arm parallel trial conducted over 4 weeks in 165 adults (18-65 years, 158 analyzed in the intention-to-treat population) with moderate insomnia (Regensburg Insomnia Scale score > 12). The tested supplement was a standardized saffron extract (Safr'Inside™, Crocus sativus), at doses of 20 mg and 30 mg (the 30 mg dose is the one used in SR-3C).
Result
After 4 weeks, the 30 mg saffron dose significantly improved perceived sleep quality compared to placebo (from week 3, maintained at week 4), and reduced perceived stress and anxio-depressive symptoms.
- +27%perceived sleep quality over 4 weeks
Clinical study #4
Safr'Inside™ (saffron extract)
Protocol
A single-center, randomized, double-blind, placebo-controlled trial conducted over 4 weeks in 52 adults aged 55 to 85 (mean age 66), cognitively healthy, with sleep complaints (PSQI>5 or ISI>10). The tested supplement was a standardized saffron extract (Safr'Inside™), at a dose of 30 mg/day (the dose used in SR-3C).
Result
After 4 weeks, saffron significantly improved perceived sleep quality (overall PSQI score) compared to placebo, which instead worsened over the period. These subjective benefits were confirmed by objective sleep measures (Dreem EEG headband): a reduction in the time to stable sleep and in sleep onset latency, while both parameters deteriorated under placebo.
- -27.6%time to stable sleep(Latency to Persistent Sleep, objective EEG measure) under saffron, versus +35.4% under placebo (p=0.003)
- -21%sleep onset latency(EEG) under saffron, versus +19% under placebo (p=0.03)
Clinical study #5
Safr'Inside™ (saffron extract)
Protocol
A crossover (3-arm), randomized, double-blind, placebo-controlled trial in 19 healthy men (18-25 years). At separate visits, spaced 28 days apart for washout, each participant received a single dose of 30 mg saffron extract (Safr'Inside™, the dose used in SR-3C), isolated safranal (0.06 mg), or placebo, 13 minutes before a standardized acute laboratory stress test (Maastricht Acute Stress Test, MAST).
Result
After a single dose, Safr'Inside™ (30 mg) significantly delayed the peak of salivary cortisol and cortisone in response to acute stress compared to placebo, reflecting modulation of the hypothalamic-pituitary-adrenal axis. Self-rated stress and anxiety (visual analogue scales) were overall reduced in the saffron/safranal groups compared to placebo.
- -39%stress from the first use
Clinical study #6
Safr'Inside™ (saffron extract)
Protocol
A single-center, randomized, double-blind, placebo-controlled trial conducted over 8 weeks (56 days) in 56 healthy adults (30 saffron / 26 placebo) reporting subclinical symptoms of anxiety, stress and/or low mood. The tested supplement was a standardized saffron extract (Safr'Inside®, 30 mg/day).
Result
After 8 weeks of supplementation, participants who received saffron showed a more pronounced reduction in their depression scores than the placebo group. Their social relationships also improved by day 56. Finally, during an acute laboratory stress test, heart rate variability remained stable in participants taking saffron, while it dropped under placebo.
- +55%improved mood over 56 days
These clinical studies were conducted on the individual ingredients, at their effective dosage. Results may vary from person to person. This food supplement is not a substitute for a healthy lifestyle or a varied and balanced diet.
